STOCK TITAN
  1. Home
  2. Sec-filings
  3. PFE
  4. [Form 4] PFIZER INC Insider Trading Activity

Pfizer (PFE) director Suzanne Nora Johnson receives 7,686 phantom stock units

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

NORA JOHNSON SUZANNE M reported acquisition or exercise transactions in this Form 4 filing.

Pfizer Inc. director Suzanne M. Nora Johnson received a grant of 7,686.539 Phantom Stock Units on April 23, 2026. Each unit represents one phantom share of Pfizer common stock and was granted at a reference price of $26.67 per unit as deferred director compensation. Following this award, her balance in these units increased to 116,982.649. The units will be settled in cash or common stock, at her election, after she retires from the Board.

Positive

  • None.

Negative

  • None.
Insider NORA JOHNSON SUZANNE M
Role null
Type Security Shares Price Value
Grant/Award Phantom Stock Units 7,686.539 $26.67 $205K
Holdings After Transaction: Phantom Stock Units — 116,982.649 shares (Direct, null)
Footnotes (1)
  1. Each unit represents one phantom share of common stock. Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors.
Phantom Stock Units granted 7,686.539 units Grant on April 23, 2026 as deferred director compensation
Reference price per unit $26.67 per unit Grant price for Phantom Stock Units
Phantom Stock Units after grant 116,982.649 units Total Phantom Stock Units following the reported transaction
Conversion price $0.00 Conversion or exercise price for Phantom Stock Units
Underlying security shares 7,686.539 shares Underlying Pfizer common stock equivalent for granted units
Transaction code A Grant, award, or other acquisition of derivative security
Phantom Stock Units financial
"Each unit represents one phantom share of common stock."
Phantom stock units are company promises that pay a cash or stock-equivalent award tied to the firm’s share price or value growth, but they do not issue actual shares. Think of them as a bonus check that moves with the stock like a mirror rather than handing over an ownership slice. Investors care because these awards can affect a company’s future cash obligations, executive incentives and reported expenses without causing share dilution.
Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors financial
"Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors."
deferred director's compensation financial
"These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors."
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
NORA JOHNSON SUZANNE M
(Last)(First)(Middle)
66 HUDSON BOULEVARD EAST
ATTN: CORPORATE SECRETARY
(Street)
NEW YORK NEW YORK 10001-2192
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/23/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Phantom Stock Units(1)04/23/2026A7,686.539(2) (3) (3)Common Stock7,686.539$26.67116,982.649D
Explanation of Responses:
1. Each unit represents one phantom share of common stock.
2. Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
3. These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors.
/s/ Shanice A. Reid, by power of atty., for Suzanne Nora Johnson04/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Pfizer (PFE) director Suzanne M. Nora Johnson report in this Form 4?

Suzanne M. Nora Johnson reported receiving 7,686.539 Phantom Stock Units as director compensation. Each unit tracks one share of Pfizer common stock and will be settled in cash or stock at her election after she retires from the Board.

Is the Pfizer (PFE) Form 4 a stock purchase or sale by the director?

The Form 4 reflects a grant of Phantom Stock Units, not an open-market stock purchase or sale. It is a compensation-related award classified as an acquisition under a director deferred compensation and unit award plan.

How many Phantom Stock Units does the Pfizer (PFE) director hold after this grant?

After the reported grant, Suzanne M. Nora Johnson holds 116,982.649 Phantom Stock Units. These units mirror Pfizer common stock value and will be settled in cash or shares when she leaves the Board, depending on her election.

What is the value reference for the Pfizer (PFE) Phantom Stock Unit grant?

The grant was based on a reference price of $26.67 per Phantom Stock Unit. This price is used to determine the number of units awarded as deferred compensation, rather than representing a cash transaction in the market.

What plan governs the Phantom Stock Units granted to the Pfizer (PFE) director?

The Phantom Stock Units were granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. This plan provides deferred compensation that tracks Pfizer’s stock and is settled after Board service ends.

When will the Pfizer (PFE) Phantom Stock Units reported in this Form 4 be settled?

These Phantom Stock Units will be settled after the director retires from Pfizer’s Board. At that time, Suzanne M. Nora Johnson may elect to receive settlement either in cash or in Pfizer common stock, consistent with the plan’s terms.